We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Vote by European Medicines Agency panel deals setback to controversial $56,000-a-year treatment
Third-quarter revenues from $56,000-per-year treatment were well below analysts’ expectation of $10m
Pharma group blames ‘misinformation’ for overshadowing approval of therapy
US drugs watchdog was under pressure after scientific outcry over controversial Biogen treatment
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
US approval of the Biogen treatment has given patients hope. But some experts worry expectations have been raised too high
FDA decision on aducanumab must bring benefits beyond Biogen’s bottom line
Lofty prices reward risky, expensive research. But aducanumab’s pricing will raise eyebrows
Campaigners hit out at high price for controversial treatment that has divided scientists
FDA signs off on first new treatment for disease in almost 20 years despite controversy over efficacy
Biogen’s aducanumab would be first new treatment in years for disease if approved by FDA
Scientists express scepticism of trial data and US regulatory process at fiery hearing
FDA staff give positive clinical review to what could be first new treatment in US for decades
Setback deals another blow to most common hypothesis about causes of the disease
Mylan had lodged dispute over a drug for multiple sclerosis
Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab
Biogen says seeking approval for aducanumab hails ‘turning point’ in fight against disease
Biotech group says new analysis shows benefits of aducanumab when taken at a high dose
Treatments for multiple sclerosis and spinal muscular atrophy help Biogen beat forecasts
Drug company’s chief Michel Vounatsos says it has the cash for share buybacks and M&A
Biogen’s aducanumab was last hope of one approach to the disease, but there are others
Drugmaker loses $18bn from market value after deciding to discontinue trials
Patients on lower doses of its drug declined more quickly than those on a placebo
International Edition
